文献速递骨软组织肉瘤与黑色素瘤

度伐利尤单抗联合曲美木单抗治疗晚期或转移性软组织与骨肉瘤:单中心2期试验

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
PubMed 文献 · Lancet Oncol · 2022-08-04

这项单中心2期试验纳入57例经治晚期或转移性肉瘤患者,接受度伐利尤单抗联合曲美木单抗治疗。12周无进展生存率为49%(95% CI 36-61),中位随访37.2个月。3-4级治疗相关不良事件21例次,最常见为脂肪酶升高(7%)、结肠炎(5%)和肺炎(5%)。

要点

  • 12周无进展生存率为49%(95% CI 36-61),中位随访37.2个月。
  • 3-4级治疗相关不良事件21例次,脂肪酶升高最常见(4例,7%)。
  • 9例(16%)患者发生治疗相关严重不良事件,1例发生5级肺炎和结肠炎。

核心结论

  • 度伐利尤单抗联合曲美木单抗是晚期或转移性肉瘤的一种有活性的治疗方案,值得在未来试验中对特定亚型进行评估。

研究设计与样本

  • 单中心2期试验,在美国德克萨斯大学MD安德森癌症中心开展。
  • 纳入18岁及以上、ECOG体能状态0或1、既往接受过至少一线全身治疗的晚期或转移性肉瘤患者,按疾病亚型分组。
  • 患者接受度伐利尤单抗1500 mg静脉注射联合曲美木单抗75 mg静脉注射共4个周期,随后度伐利尤单抗单药每4周一次,最长12个月。
  • 主要终点为意向治疗人群(至少接受一剂治疗的所有患者)的12周无进展生存率;安全性同样在意向治疗人群中分析。
  • 2016年8月17日至2018年4月9日期间入组62例患者,其中57例(92%)接受治疗并纳入意向治疗人群。

主要发现

  • 中位随访37.2个月(IQR 1.8-10.1),12周无进展生存率为49%(95% CI 36-61)。
  • 报告21例次3-4级治疗相关不良事件,最常见为脂肪酶升高(57例中4例,7%)、结肠炎(3例,5%)和肺炎(3例,5%)。
  • 9例(16%)患者发生治疗相关严重不良事件。
  • 1例患者发生5级肺炎和结肠炎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few standard treatment options are available for patients with metastatic sarcomas. We did this trial to evaluate the efficacy, safety, and changes in the tumour microenvironment for durvalumab, an anti-PD-L1 drug, and tremelimumab, an anti-CTLA-4 drug, across multiple sarcoma subtypes. METHODS: In this single-centre phase 2 trial, done at The University of Texas MD Anderson Cancer Center (Houston, TX USA), patients aged 18 years or older with advanced or metastatic sarcoma with an Eastern Cooperative Oncology Group performance status of 0 or 1 who had received at least one previous line of systemic therapy were enrolled in disease subtype-specific groups (liposarcoma, leiomyosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma, osteosarcoma, alveolar soft-part sarcoma, chordoma, and other sarcomas). Patients received 1500 mg intravenous durvalumab and 75 mg intravenous tremelimumab for four cycles, followed by durvalumab alone every 4 weeks for up to 12 months. The primary endpoint was progression-free survival at 12 weeks in the intention-to-treat population (all patients who received at least one dose of treatment). Safety was also analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02815995, and is completed. FINDINGS: Between Aug 17, 2016, and April 9, 2018, 62 patients were enrolled, of whom 57 (92%) received treatment and were included in the intention-to-treat population. With a median follow-up of 37·2 months (IQR 1·8-10·1), progression-free survival at 12 weeks was 49% (95% CI 36-61). 21 grade 3-4 treatment-related adverse events were reported, the most common of which were increased lipase (four [7%] of 57 patients), colitis (three [5%] patients), and pneumonitis (three [5%] patients). Nine (16%) patients had a treatment related serious adverse event. One patient had grade 5 pneumonitis and colitis. INTERPRETATION: The combination of durvalumab and tremelimumab is an active treatment regimen for advanced or metastatic sarcoma and merits evaluation in specific subsets in future trials. FUNDING: AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Somaiah N, Conley AP, Parra ER, et al. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022. PMID: 35934010. doi:10.1016/S1470-2045(22)00392-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。